Immunotherapy in the form of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have revolutionized cancer care in the past decades, in many cases replacing conventional chemotherapy or delivering significant survival improvement when combined with standard therapy [5]. This evidence concerns the gene PDCD1 and cancer.